Abstract

Brain connectivity profiles seeding from deep brain stimulation (DBS) electrodes have emerged as informative tools to estimate outcome variability across DBS patients. Given the limitations of acquiring and processing patient-specific diffusion-weighted imaging data, a number of studies have employed normative atlases of the human connectome. To date, it remains unclear whether patient-specific connectivity information would strengthen the accuracy of such analyses. Here, we compared similarities and differences between patient-specific, disease-matched and normative structural connectivity data and their ability to predict clinical improvement.Data from 33 patients suffering from Parkinson's Disease who underwent surgery at three different centers were retrospectively collected. Stimulation-dependent connectivity profiles seeding from active contacts were estimated using three modalities, namely patient-specific diffusion-MRI data, age- and disease-matched or normative group connectome data (acquired in healthy young subjects). Based on these profiles, models of optimal connectivity were calculated and used to estimate clinical improvement in out of sample data.All three modalities resulted in highly similar optimal connectivity profiles that could largely reproduce findings from prior research based on this present novel multi-center cohort. In a data-driven approach that estimated optimal whole-brain connectivity profiles, out-of-sample predictions of clinical improvements were calculated. Using either patient-specific connectivity (R = 0.43 at p = 0.001), an age- and disease-matched group connectome (R = 0.25, p = 0.048) and a normative connectome based on healthy/young subjects (R = 0.31 at p = 0.028), significant predictions could be made.Our results of patient-specific connectivity and normative connectomes lead to similar main conclusions about which brain areas are associated with clinical improvement. Still, although results were not significantly different, they hint at the fact that patient-specific connectivity may bear the potential of explaining slightly more variance than group connectomes. Furthermore, use of normative connectomes involves datasets with high signal-to-noise acquired on specialized MRI hardware, while clinical datasets as the ones used here may not exactly match their quality. Our findings support the role of DBS electrode connectivity profiles as a promising method to investigate DBS effects and to potentially guide DBS programming.

Highlights

  • Deep brain stimulation (DBS) is a well-established treatment for Parkinson’s disease (PD), alleviating motor symptoms and improving quality of life (Deuschl et al, 2006; Schuepbach et al, 2013)

  • Our DBS cohort included 33 patients enrolled at 3 independent centers (7 females, mean age 62.5 ±1.6 years)

  • We show that optimal connectivity profiles that were associated with good clinical improvement in our sample followed the same overall distribution irrespective of the applied connectivity metric

Read more

Summary

Introduction

Deep brain stimulation (DBS) is a well-established treatment for Parkinson’s disease (PD), alleviating motor symptoms and improving quality of life (Deuschl et al, 2006; Schuepbach et al, 2013). Maximal improvement in cardinal motor symptoms was associated with connectivity of DBS electrodes to different cortical regions: tremor control with connectivity to primary motor cortex (M1), bradykinesia with the supplementary motor area (SMA) and rigidity to both prefrontal cortex (PFC) and SMA These two studies acquired dMRI in each patient preoperatively. Preoperative dMRI data is not routinely acquired preoperatively in a large fraction of DBS patients and cannot be acquired postoperatively (without substantial constraints) This is especially relevant in novel indications such as Alzheimer’s Disease (Baldermann et al, 2018; Ponce et al, 2016) or psychiatric indications (Hamani et al, 2011; Huys et al, 2019) where limited numbers of patients undergo surgery, even on a world-wide scale. The same applies to “classical diseases” (such as dystonia) that are treated with unconventional targets (such as the STN), again resulting in a low number of available patients, world-wide (Ostrem et al, 2011; Yao et al, 2019)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call